Escitalopram
Escitalopram (Leksapro, Cipraleks, Seropleks, Leksamil, Leksam) je antidepresiv iz klase selektivnih inhibitora preuzimanja serotonina (SSRI). On je odobren od strane FDA za lečenje odraslih osoba sa kliničkom depresijom.[5] i generalizovanim anksioznim poremećajem[6] Escitalopram je S-stereoizomer (enantiomer) ranijeg Lundbeckovog leka citaloprama, odakle potiče ime escitalopram. Escitalopram je poznat po svojoj visokoj selektivnosti za inhibiciju preuzimanja serotonina. On poseduje tipične nuspojave SSRI klase.
| |||
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 128196-01-0 | ||
| ATC kod | N06AB10 | ||
| PubChem[1][2] | 146570 | ||
| DrugBank | APRD00683 | ||
| ChemSpider[3] | 129277 | ||
| UNII | 4O4S742ANY 
| ||
| ChEMBL[4] | CHEMBL1508
| ||
| Hemijski podaci | |||
| Formula | C20H21FN2O | ||
| Mol. masa | 324.392 g/mol (414.43 kao oksalat) | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakokinetički podaci | |||
| Bioraspoloživost | 80% | ||
| Vezivanje za proteine plazme | ~56% | ||
| Metabolizam | Jetra, posebno enzimi CYP3A4 i CYP2C19 | ||
| Poluvreme eliminacije | 27–32 časa | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | Rx Only (U.S) POM (U.K) | ||
| Način primene | Oralno | ||
Референце uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Kennedy SH, Andersen HF, Thase ME (January 2009). „Escitalopram in the treatment of major depressive disorder: a meta-analysis”. Current Medical Research and Opinion 25 (1): 161–75. DOI:10.1185/03007990802622726. PMID 19210149. Pristupljeno 2011-05-06.
- ↑ Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, Andreescu C, Butters MA, Reynolds CF (January 2009). „Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial”. JAMA : the Journal of the American Medical Association 301 (3): 295–303. DOI:10.1001/jama.2008.977. PMC 2840403. PMID 19155456. Pristupljeno 2011-05-06.[mrtav link]
Dodatna literatura uredi
- Royal Pharmaceutical Society of Great Britain (September 2009). British National Formulary (BNF 58). UK: BMJ Group and RPS Publishing. ISBN 9780853697787. Arhivirano iz originala na datum 2015-05-13. Pristupljeno 2014-04-05.
- Royal Geographical Society (2008). British National Formulary: September 2008 (British National Formulary). London: Pharmaceutical Press. ISBN 0-85369-778-7.
